logo
logo

Saliogen Therapeutics Closes $115 Million Oversubscribed Series B Financing To Advance Gene Coding™ – A New Category Of Genetic Medicine

Saliogen Therapeutics Closes $115 Million Oversubscribed Series B Financing To Advance Gene Coding™ – A New Category Of Genetic Medicine

01/05/22, 8:00 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$115 million
Round Type
series b
SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine, today announced the completion of an oversubscribed and up-sized $115 million Series B financing.

Company Info

Company
Salio Gen
Location
cambridge, maryland, united states
Additional Info
The Gene Coding company.